Screening of traditional medicinal plant extracts and compounds identifies a potent anti-leishmanial diarylheptanoid from Siphonochilus aethiopicus

Available anti-leishmanial drugs are associated with toxic side effects, necessitating the search for safe and effective alternatives. This study is focused on identifying traditional medicinal plant natural products for anti-leishmanial potential and possible mechanism of action. Compounds S and T. cordifolia residual fraction (TC-5) presented the best anti-leishmanial activity (IC50: 0.446 and 1.028 mg/ml) against promastigotes at 48 h and less cytotoxicity to THP-1 macrophages. These test agents elicited increased expression of pro-inflammatory cytokines; TNFα and IL-12. In infected untreated macrophages, NO release was suppressed but was significantly (p < 0.05) increased in infected cells treated with compound S. Importantly, Compound S was found to interact with LdTopoIIdimer in silico, resulting in a likely reduced ability of nucleic acid (dsDNA)-remodelling and, as a result, parasite proliferation in vitro. Thereby, Compound S possesses anti-leishmanial activity and this effect occurs via a Th1-mediated pro-inflammatory response. An increase in NO release and its inhibitory effect on LdTopoII may also contribute to the anti-leishmanial effect of compound S. These results show the potential of this compound as a potential starting point for the discovery of novel anti-leishmanial leads.Communicated by Ramaswamy H. Sarma.

[1]  P. Srivastava,et al.  Host SUMOylation Pathway Negatively Regulates Protective Immune Responses and Promotes Leishmania donovani Survival , 2022, Frontiers in Cellular and Infection Microbiology.

[2]  Jeremy D. DeBarry,et al.  VEuPathDB: the eukaryotic pathogen, vector and host bioinformatics resource center , 2021, Nucleic Acids Res..

[3]  N. Al-Tannak,et al.  Antiplasmodial activity of a novel diarylheptanoid from Siphonochilus aethiopicus , 2020, Natural product research.

[4]  Samuel Ehiabhi Okhale,et al.  Ethnopharmacology-aided antiplasmodial evaluation of six selected plants used for malaria treatment in Nigeria. , 2020, Journal of ethnopharmacology.

[5]  Vijeta Sharma,et al.  Natural Product Inspired Novel Indole based Chiral Scaffold Kills Human Malaria Parasites via Ionic Imbalance Mediated Cell Death , 2019, Scientific Reports.

[6]  U. Anand,et al.  A Comprehensive Review on Medicinal Plants as Antimicrobial Therapeutics: Potential Avenues of Biocompatible Drug Discovery , 2019, Metabolites.

[7]  R. Aebersold,et al.  The Chaperonin TRiC/CCT Associates with Prefoldin through a Conserved Electrostatic Interface Essential for Cellular Proteostasis , 2019, Cell.

[8]  R. Madhubala,et al.  The arginine sensing and transport binding sites are distinct in the human pathogen Leishmania , 2019, PLoS neglected tropical diseases.

[9]  S. Pati,et al.  Plasmodium palmitoylation machinery engineered in E. coli for high‐throughput screening of palmitoyl acyl‐transferase inhibitors , 2019, FEBS open bio.

[10]  Muhammed Tilahun Muhammed,et al.  Homology modeling in drug discovery: Overview, current applications, and future perspectives , 2018, Chemical biology & drug design.

[11]  M. Locatelli,et al.  A Review on the Dietary Flavonoid Tiliroside. , 2018, Comprehensive reviews in food science and food safety.

[12]  D. Boakye,et al.  In vitro antiprotozoan activity and mechanisms of action of selected Ghanaian medicinal plants against Trypanosoma, Leishmania, and Plasmodium parasites , 2018, Phytotherapy research : PTR.

[13]  O. Ogbole,et al.  Antimicrobial and antiprotozoal activities of twenty-four Nigerian medicinal plant extracts , 2018, South African Journal of Botany.

[14]  Torsten Schwede,et al.  SWISS-MODEL: homology modelling of protein structures and complexes , 2018, Nucleic Acids Res..

[15]  W. Sippl,et al.  Compounds from African Medicinal Plants with Activities Against Selected Parasitic Diseases: Schistosomiasis, Trypanosomiasis and Leishmaniasis , 2018, Natural Products and Bioprospecting.

[16]  G. A. Gutiérrez-Rebolledo,et al.  Natural compounds and extracts from Mexican medicinal plants with anti-leishmaniasis activity: An update. , 2017, Asian Pacific journal of tropical medicine.

[17]  A. Nadhman,et al.  Plants as Antileishmanial Agents: Current Scenario , 2016, Phytotherapy research : PTR.

[18]  Z. Shinwari,et al.  Ethnomedicines and anti-parasitic activities of Pakistani medicinal plants against Plasmodia and Leishmania parasites , 2016, Annals of Clinical Microbiology and Antimicrobials.

[19]  O. Singh,et al.  Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective , 2016, Infectious Diseases of Poverty.

[20]  A. Amaral,et al.  Natural Products: Insights into Leishmaniasis Inflammatory Response , 2015, Mediators of inflammation.

[21]  M. Idu,et al.  Ethnomedicinal survey of plants used in the treatment of malaria in Southern Nigeria. , 2015, Journal of ethnopharmacology.

[22]  P. Veras,et al.  Advances in Development of New Treatment for Leishmaniasis , 2015, BioMed research international.

[23]  N. Ghorai,et al.  Protective effect of Croton caudatus Geisel leaf extract against experimental visceral leishmaniasis induces proinflammatory cytokines in vitro and in vivo. , 2015, Experimental parasitology.

[24]  K. Otun,et al.  Chemical Composition, Antioxidant and Antimicrobial Potentials of Icacina trichantha Oliv. Leaf Extracts , 2015 .

[25]  M. Wilson,et al.  Eosinophils and mast cells in leishmaniasis , 2014, Immunologic research.

[26]  David J Newman,et al.  Natural products: a continuing source of novel drug leads. , 2013, Biochimica et biophysica acta.

[27]  B. Schmidt,et al.  Structure of a topoisomerase II-DNA-nucleotide complex reveals a new control mechanism for ATPase activity , 2012, Nature Structural &Molecular Biology.

[28]  N. Reiner,et al.  Myeloid Cell IL-10 Production in Response to Leishmania Involves Inactivation of Glycogen Synthase Kinase-3β Downstream of Phosphatidylinositol-3 Kinase , 2012, The Journal of Immunology.

[29]  Evan Bolton,et al.  PubChem's BioAssay Database , 2011, Nucleic Acids Res..

[30]  Yang Zhang,et al.  Improving the physical realism and structural accuracy of protein models by a two-step atomic-level energy minimization. , 2011, Biophysical journal.

[31]  V. Hannaert,et al.  In vitro antitrypanosomal and antileishmanial activity of plants used in Benin in traditional medicine and bio-guided fractionation of the most active extract. , 2011, Journal of ethnopharmacology.

[32]  A. Renslo,et al.  Identification of Small Molecule Lead Compounds for Visceral Leishmaniasis Using a Novel Ex Vivo Splenic Explant Model System , 2011, PLoS neglected tropical diseases.

[33]  Margarida Saraiva,et al.  The regulation of IL-10 production by immune cells , 2010, Nature Reviews Immunology.

[34]  M. Salvador,et al.  Bioactivity of Flavonoids Isolated from Lychnophora markgravii against Leishmania amazonensis Amastigotes , 2009, Zeitschrift fur Naturforschung. C, Journal of biosciences.

[35]  A. Giménez,et al.  An Alkaloid Extract of Evanta, Traditionally Used as Anti‐leishmania Agent in Bolivia, Inhibits Cellular Proliferation and Interferon‐γ Production in Polyclonally Activated Cells , 2009, Scandinavian journal of immunology.

[36]  Xiaohua Ma,et al.  Mechanisms of drug combinations: interaction and network perspectives , 2009, Nature Reviews Drug Discovery.

[37]  K. Ajibesin,et al.  Ethnobotanical survey of Akwa Ibom State of Nigeria. , 2008, Journal of ethnopharmacology.

[38]  E. von Stebut,et al.  Distinct roles for IL-1 receptor type I signaling in early versus established Leishmania major infections. , 2006, The Journal of investigative dermatology.

[39]  A. Celada,et al.  Arginase and polyamine synthesis are key factors in the regulation of experimental leishmaniasis in vivo , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[40]  Y. Belkaid,et al.  Interleukin 1α Promotes Th1 Differentiation and Inhibits Disease Progression in Leishmania major–susceptible BALB/c Mice , 2003, The Journal of experimental medicine.

[41]  Wan-Wan Lin,et al.  Inhibition of cytokine‐induced JAK‐STAT signalling pathways by an endonuclease inhibitor aurintricarboxylic acid , 2002, British journal of pharmacology.

[42]  D. Sacks,et al.  The immunology of susceptibility and resistance to Leishmania major in mice , 2002, Nature Reviews Immunology.

[43]  Wan-Wan Lin,et al.  Aurintricarboxylic acid protects against cell death caused by lipopolysaccharide in macrophages by decreasing inducible nitric-oxide synthase induction via IkappaB kinase, extracellular signal-regulated kinase, and p38 mitogen-activated protein kinase inhibition. , 2002, Molecular pharmacology.

[44]  B. Liu,et al.  Role of Nitric Oxide in Inflammation‐Mediated Neurodegeneration , 2002, Annals of the New York Academy of Sciences.

[45]  H. Rui,et al.  Activation of the Jak2-Stat5 Signaling Pathway in Nb2 Lymphoma Cells by an Anti-apoptotic Agent, Aurintricarboxylic Acid* , 1998, The Journal of Biological Chemistry.

[46]  R. G. Kemp,et al.  Aurintricarboxylic acid is a potent inhibitor of phosphofructokinase. , 1989, The Biochemical journal.

[47]  L. Gradoni,et al.  The Leishmaniases: Old Neglected Tropical Diseases , 2018, Springer International Publishing.

[48]  L. Liaudet,et al.  Nitric oxide and peroxynitrite in health and disease. , 2007, Physiological reviews.

[49]  S. Gordon.  Alternative activation of macrophages , 2003, Nature Reviews Immunology.